Aktienanalyse zu Rocket Pharmaceuticals Inc (RCKT)RCKTRocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Rocket Pharmaceuticals Inc appears to be a good buy right now due to its recent upgrade by Needham to a Buy rating with a price target of $9, suggesting a potential upside of approximately 150% from the current price of $2.47. Additionally, the stock has shown a positive momentum with a 5-day change of +8.33%, indicating increasing investor interest. The main risk to consider is the company's forward P/E ratio, which is currently at 0, reflecting uncertainty in future earnings projections.

1 analysts cover RCKT: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 8.63.